242 related articles for article (PubMed ID: 12192613)
1. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
Kaiser R; Tremblay PB; Klufmöller F; Roots I; Brockmöller J
Mol Psychiatry; 2002; 7(7):695-705. PubMed ID: 12192613
[TBL] [Abstract][Full Text] [Related]
2. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
[TBL] [Abstract][Full Text] [Related]
3. Association study between antipsychotics- induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia.
Kang SG; Lee HJ; Choi JE; Park YM; Park JH; Han C; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
Neuropsychobiology; 2008; 57(1-2):49-54. PubMed ID: 18451638
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders.
Lafuente A; Bernardo M; Mas S; Crescenti A; Aparici M; Gasso P; Deulofeu R; Mane A; Catalan R; Carne X
Psychiatry Res; 2008 Nov; 161(2):131-41. PubMed ID: 18922583
[TBL] [Abstract][Full Text] [Related]
6. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients.
Zai CC; Tiwari AK; Basile V; De Luca V; Müller DJ; King N; Voineskos AN; Remington G; Meltzer HY; Lieberman JA; Potkin SG; Kennedy JL
Pharmacogenomics J; 2009 Jun; 9(3):168-74. PubMed ID: 19238168
[TBL] [Abstract][Full Text] [Related]
7. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia.
Segman RH; Goltser T; Heresco-Levy U; Finkel B; Shalem R; Schlafman M; Yakir A; Greenberg D; Strous R; Lerner A; Shelevoy A; Lerer B
Pharmacogenomics J; 2003; 3(5):277-83. PubMed ID: 14583797
[TBL] [Abstract][Full Text] [Related]
8. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.
Wu S; Xing Q; Gao R; Li X; Gu N; Feng G; He L
Neurosci Lett; 2005 Mar; 376(1):1-4. PubMed ID: 15694263
[TBL] [Abstract][Full Text] [Related]
9. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism.
Tiwari AK; Deshpande SN; Lerer B; Nimgaonkar VL; Thelma BK
Pharmacogenomics J; 2007 Oct; 7(5):305-11. PubMed ID: 16969362
[TBL] [Abstract][Full Text] [Related]
10. Influence of DRD2 polymorphisms on the clinical outcomes of patients with schizophrenia.
Zahari Z; Teh LK; Ismail R; Razali SM
Psychiatr Genet; 2011 Aug; 21(4):183-9. PubMed ID: 21206399
[TBL] [Abstract][Full Text] [Related]
11. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.
Segman RH; Heresco-Levy U; Finkel B; Goltser T; Shalem R; Schlafman M; Dorevitch A; Yakir A; Greenberg D; Lerner A; Lerer B
Mol Psychiatry; 2001 Mar; 6(2):225-9. PubMed ID: 11317227
[TBL] [Abstract][Full Text] [Related]
12. Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding.
Mihara K; Kondo T; Higuchi H; Takahashi H; Yoshida K; Shimizu T; Kaneko S
Am J Med Genet; 2002 Aug; 114(6):693-5. PubMed ID: 12210290
[TBL] [Abstract][Full Text] [Related]
13. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.
Yasui-Furukori N; Saito M; Tsuchimine S; Nakagami T; Sato Y; Sugawara N; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1491-5. PubMed ID: 18579277
[TBL] [Abstract][Full Text] [Related]
14. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.
Basile VS; Ozdemir V; Masellis M; Meltzer HY; Lieberman JA; Potkin SG; Macciardi FM; Petronis A; Kennedy JL
Mol Psychiatry; 2001 Mar; 6(2):230-4. PubMed ID: 11317228
[TBL] [Abstract][Full Text] [Related]
15. Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication.
Greenbaum L; Strous RD; Kanyas K; Merbl Y; Horowitz A; Karni O; Katz E; Kotler M; Olender T; Deshpande SN; Lancet D; Ben-Asher E; Lerer B
Pharmacogenet Genomics; 2007 Jul; 17(7):519-28. PubMed ID: 17558307
[TBL] [Abstract][Full Text] [Related]
16. No association of dopamine receptor sensitivity in vivo with genetic predisposition for alcoholism and DRD2/DRD3 gene polymorphisms in alcohol dependence.
Wiesbeck GA; Dürsteler-MacFarland KM; Wurst FM; Walter M; Petitjean S; Müller S; Wodarz N; Böning J
Addict Biol; 2006 Mar; 11(1):72-5. PubMed ID: 16759339
[TBL] [Abstract][Full Text] [Related]
17. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
18. The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and -141C Ins/Del polymorphisms.
Himei A; Koh J; Sakai J; Inada Y; Akabame K; Yoneda H
Psychiatry Clin Neurosci; 2002 Feb; 56(1):97-102. PubMed ID: 11929577
[TBL] [Abstract][Full Text] [Related]
19. No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response.
Zhang ZJ; Yao ZJ; Zhang XB; Chen JF; Sun J; Yao H; Hou G; Zhang XB
Acta Pharmacol Sin; 2003 Mar; 24(3):235-40. PubMed ID: 12617772
[TBL] [Abstract][Full Text] [Related]
20. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.
Gunes A; Scordo MG; Jaanson P; Dahl ML
Psychopharmacology (Berl); 2007 Mar; 190(4):479-84. PubMed ID: 17102980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
